山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2014年
23期
60-63
,共4页
b-DNA技术%人乳头状瘤病毒%E6基因%E7基因%宫颈高度上皮内瘤样病变
b-DNA技術%人乳頭狀瘤病毒%E6基因%E7基因%宮頸高度上皮內瘤樣病變
b-DNA기술%인유두상류병독%E6기인%E7기인%궁경고도상피내류양병변
b-DNA technology%human papillomavirus%E6 gene%E7 gene%high-grade cervical intraepithelial neo-plasias
目的:评价高危型人乳头状瘤病毒( HPV) E6/E7 mRNA检测对宫颈病变的诊断价值。方法520例患者采用b-DNA技术检测HPV E6/E7 mRNA,并用宫颈液基细胞学( TCT)行宫颈细胞学检查,对其中任何一项阳性者做阴道镜下宫颈活组织检查,以组织病理为金标准,计算HPV E6/E7 mRNA阳性对高级别宫颈上皮内瘤样病变( CIN)、宫颈浸润癌诊断的灵敏度、特异度、阳性预测值、阴性预测值,并与TCT检查进行比较。结果520例患者中HPV E6/E7 mRNA阳性158例, TCT异常222例。 TCT 异常者中HPV E6/E7 mRNA阳性率较TCT 正常者中HPV E6/E7 mRNA阳性率高(P<0.05)。146例慢性宫颈炎、CINⅠ级患者与124例高级别CIN、宫颈浸润癌患者中HPV E6/E7 mRNA阳性率比较,P<0.05。 HPV E6/E7 mRNA阳性对高级别CIN及宫颈浸润癌诊断的灵敏度、特异度、阳性预测值、阴性预测值分别为74.19%、83.33%、58.23%、71.43%,TCT 检查分别为81.53%、69.44%、81.45%、92.28%,两者特异度及阳性预测值比较, P均<0.05。结论在宫颈癌筛查中检测高危型HPV E6/E7 mRNA对预测高级别CIN,尤其对评估癌症风险有重要的临床价值。
目的:評價高危型人乳頭狀瘤病毒( HPV) E6/E7 mRNA檢測對宮頸病變的診斷價值。方法520例患者採用b-DNA技術檢測HPV E6/E7 mRNA,併用宮頸液基細胞學( TCT)行宮頸細胞學檢查,對其中任何一項暘性者做陰道鏡下宮頸活組織檢查,以組織病理為金標準,計算HPV E6/E7 mRNA暘性對高級彆宮頸上皮內瘤樣病變( CIN)、宮頸浸潤癌診斷的靈敏度、特異度、暘性預測值、陰性預測值,併與TCT檢查進行比較。結果520例患者中HPV E6/E7 mRNA暘性158例, TCT異常222例。 TCT 異常者中HPV E6/E7 mRNA暘性率較TCT 正常者中HPV E6/E7 mRNA暘性率高(P<0.05)。146例慢性宮頸炎、CINⅠ級患者與124例高級彆CIN、宮頸浸潤癌患者中HPV E6/E7 mRNA暘性率比較,P<0.05。 HPV E6/E7 mRNA暘性對高級彆CIN及宮頸浸潤癌診斷的靈敏度、特異度、暘性預測值、陰性預測值分彆為74.19%、83.33%、58.23%、71.43%,TCT 檢查分彆為81.53%、69.44%、81.45%、92.28%,兩者特異度及暘性預測值比較, P均<0.05。結論在宮頸癌篩查中檢測高危型HPV E6/E7 mRNA對預測高級彆CIN,尤其對評估癌癥風險有重要的臨床價值。
목적:평개고위형인유두상류병독( HPV) E6/E7 mRNA검측대궁경병변적진단개치。방법520례환자채용b-DNA기술검측HPV E6/E7 mRNA,병용궁경액기세포학( TCT)행궁경세포학검사,대기중임하일항양성자주음도경하궁경활조직검사,이조직병리위금표준,계산HPV E6/E7 mRNA양성대고급별궁경상피내류양병변( CIN)、궁경침윤암진단적령민도、특이도、양성예측치、음성예측치,병여TCT검사진행비교。결과520례환자중HPV E6/E7 mRNA양성158례, TCT이상222례。 TCT 이상자중HPV E6/E7 mRNA양성솔교TCT 정상자중HPV E6/E7 mRNA양성솔고(P<0.05)。146례만성궁경염、CINⅠ급환자여124례고급별CIN、궁경침윤암환자중HPV E6/E7 mRNA양성솔비교,P<0.05。 HPV E6/E7 mRNA양성대고급별CIN급궁경침윤암진단적령민도、특이도、양성예측치、음성예측치분별위74.19%、83.33%、58.23%、71.43%,TCT 검사분별위81.53%、69.44%、81.45%、92.28%,량자특이도급양성예측치비교, P균<0.05。결론재궁경암사사중검측고위형HPV E6/E7 mRNA대예측고급별CIN,우기대평고암증풍험유중요적림상개치。
Objective To evaluate the clinical value of human papillomavirus ( HPV) E6/E7 mRNA detection in diagnosis of cervical lesions.Methods Totally 520 patients were examined with b-DNA technology to detect HR-HPV E6/E7mRNA and the cervical cytological examination with liquid-based cytology (TCT).Women with cytologi-cal abnormalities or HR-HPV E6/E7 mRNA positive results underwent colposcopy and cervical biopsy .We compared the sensitivity, specificity, positive predictive value and negative predictive value between the HPV E6/E7mRNA and TCT for the detection of high-grade cervical intraepithelial neoplasias ( CIN) and cervical cancer ( CC) .Results A-mong 520 patients, 158 cases were found HPV E6/E7mRNA positive and 222 cases got TCT abnormal.The positive rate of HPV E6/E7 mRNA with abnormal results in TCT abnormal group was higher than that of the normal group ( P<0.05) .There was difference in the positive rate of HPV E6/E7mRNA between the group who got chronic cervicitis or low-grade intraepithelial neoplasias (CINⅠ) and the group who got high-grade CIN and CC (P<0.05).For the detection of high-grade CIN and CC, the sensitivity of HPVE6/E7 mRNA and TCT was 74.19% and 81.53%, re-spectively; the specificity was 83.33% and 69.44%, respectively; the positive predictive value was 58.23% and 81.45%, respectively; and the negative predictive value was 71.43% and 92.28% respectively.The specificity and positive predictive value was statistically different between the two groups (all P<0.05).Conclusion In cervi-cal cancer screening, high-risk HPV E6/E7 mRNA detection in predicting high-grade CIN has high clinical value, es-pecially for assessing the risk of malignancy.